Finch Therapeutics reports preliminary cash of $133.5M as of Dec 31, 2021

Finch Therapeutics Group, Inc.

Preliminary cash and cash equivalents of approximately $133.5M as of Dec 31, 2021.
CEO Mark Smith to present at J.P. Morgan Healthcare Conference on Jan 13, 2022.
Updated corporate presentation posted on company website for investor meetings.
Year-end audit ongoing; final cash balance may differ from preliminary estimate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.